Noradrenaline Might Enhance Assertive Human Social Behaviours: An Investigation in a Flatmate Relationship

Objective: The aim of the present study was to explore the role of noradrenaline on the social behaviour of healthy volunteers when they were interacting with a familiar person, their flatmate. Interaction with the flatmate was explored in a cooperative game situation. Methods: Ten pairs of same-sex healthy volunteer flatmates aged 18-25 years were recruited for the experiment. All volunteers gave written informed consent and the study was approved by the institutional ethical committee. A randomised, double blind, placebo-controlled crossover trial of reboxetine versus placebo was conducted. In each of the 10 pairs of volunteers, one (subject) volunteered to take the tablets and the other (flatmate) received no treatment. Reboxetine (4 mg/bd) and placebo were administered orally as identical capsules for 2 weeks. The subjects were randomly assigned to receive either reboxetine or placebo first and there was a two-week washout period following the first treatment. At baseline and the end of each treatment, they filled in the Beck Depression Inventory (BDI), Social Adapation Self-Evaluation Scale (SASS), and Aggression Questionnaire (AQ). Then, they were instructed to play the Tangrams game. This task elicits face-valid social behaviours such as cooperation, giving commands and unilateral grasps. Results: Analysis of covariance showed that there was a statistical trend for reboxetine treatment to increase commands (p=0.055). Conclusion: This study presents preliminary evidence that two weeks' enhancement of noradrenaline transmission induced by reboxetine makes healthy volunteers more self-confident and assertive.

References

• 1 Abramson LY, Metalsky GI, Alloy LB. Hopelessness depression: a theory-based subtype of depression.  Psychol Rev. 1989;  96 358-372
• 2 Atmaca M, Tezcan E, Kuloglu M. An open clinical trial of reboxetine in the treatment of social phobia.  J Clin Psychopharmacol. 2003;  23 417-419
• 3 Beck AT, Steer R, Garbin M. Psychometric properties of the Beck Depression Inventory: 25 years of evaluation.  Clin Psychol Rev. 1988;  8 77-100
• 4 Bosc M, Dubini A, Polin V. Development and validation of a social functioning scale, the Social Adaptation Self-evaluation Scale.  Eur Neuropsychopharmacol. 1997;  7 ((Suppl)) 57-70
• 5 Brodkin ES, McDougle CJ, Naylor ST, Cohen DJ, Price LH. Clomipramine in adults with pervasive developmental disorders: a prospective open-label investigation.  J Child Adolesc Psychopharmacol. 1997;  7 109-121
• 6 Buss AH, Perry M. The aggression questionnaire.  J Pers Soc Psych. 1992;  59 73-81
• 7 Cloninger CR, Svrakic DM, Przybeck TR. A psychobiological model of temperament and character.  Arch Gen Psychiatry. 1993;  50 975-990
• 8 Coyne JC. Depression and the response of others.  J Abnorm Psychol. 1976;  85 186-193
• 9 Dubini A, Bosc M, Polin V. Do noradrenaline and serotonin differentially affect social motivation and behaviour?.  Eur Neuropsychopharmacol. 1997;  7 ((Suppl)) 49-55
• 10 Fossi L, Faravelli C, Paoli M. The ethological approach to the assessment of depressive disorders.  J Nerv Ment Dis. 1984;  172 332-341
• 11 Gilbert P. Submissive behaviour and psychopathology.  Br J Clin Psychol. 1997;  36 467-488
• 12 Gould GG, Pardon MC, Morilak DA, Frazer A. Regulatory effects of reboxetine treatment alone, or following paroxetine treatment, on brain noradrenergic and serotonergic systems.  Neuropsychopharmacol. 2003;  28 1633-1641
• 13 Keller M. Role of serotonin and noradrenaline in social dysfunction: a review of data on reboxetine and the Social Adaptation Self-evaluation Scale (SASS).  Gen Hosp Psychiatry. 2001;  23 15-19
• 14 Knutson B, Wolkowitz WM, Cole SW, Chan T, Moore EA, Johnson RC, Terpstra J, Turner RA, Reus VI. Selective alteration of personality and social behavior by serotonergic intervention.  Am J Psychiatry. 1998;  155 373-379
• 15 Libet JM, Lewinsohn PM. Concept of social skill with special reference to the behavior of depressed persons.  J Consult Clin Psychol. 1973;  40 304-312
• 16 Raleigh MJ, McGuire MT, Brammer GL, Pollack DB, Yuwiler A. Serotonergic mechanisms promotes dominance acquisition in adult male vervet monkeys.  Brain Res. 1991;  559 181-190
• 17 Schubert DS. Increase of assertiveness by medication.  Integr Psychiatry. 1988;  6 223-228
• 18 Senn S. Cross-over Trials in Clinical Research. Wiley New York; 1993
• 19 Stassen HH, Kuny S, Hell D. The speech analysis approach to determining onset of improvement under antidepressants.  Eur Neuropsychopharmacol. 1998;  8 303-310
• 20 Sullivan HS. The interpersonal theory of psychiatry. Norton & Company NY; 1997
• 21 Tse WS, Bond AJ. Development and Validation of the Two-Dimensional Social Interaction Scale (2DSIS).  Psychiat Res. 2001;  103 249-260
• 22 Tse WS, Bond AJ. Difference in serotonergic and noradrenergic regulation of human social behaviours.  Psychopharmacology. 2002;  159 216-221
• 23 Tse WS, Bond AJ. Reboxetine promotes social bonding in healthy volunteers.  J Psychopharmacol. 2003;  17 165-171
• 24 Tse WS, Bond AJ. The impact of depression on social skills: a review.  J Nerv Ment Dis. 2004;  196 260-268
• 25 Versiani M, Amin M, Chouinard G. Double-blind placebo-controlled study with reboxetine in inpatients with severe major depressive disorder.  J Clin Psychopharmacol. 2000;  20 28-34
• 26 Weissman MM. Social functioning and the treatment of depression.  J Clin Psychiatry. 2000;  61 33-38

Correspondence